Assessing the impacts of COVID-19 vaccination programme’s timing and speed on health benefits, cost-effectiveness, and relative affordability in 27 African countries

Table 2 Vaccine unit costs by roll-out scenario and vaccine type

Roll-out scenario		Vaccine type	Lower limit ($)	First quartile ($)	Median ($)	Third quartile ($)	Upper limit ($)
Start date	Roll-out rate	Vaccine type	Lower limit ($)	First quartile ($)	Median ($)	Third quartile ($)	Upper limit ($)
01 August 2021	Medium	Viral vector vaccine	4.96	6.04	6.92	8.44	15.40
	Fast	Viral vector vaccine	2.54	3.61	4.49	6.02	12.97
	Medium	mRNA vaccine	14.2	15.27	16.15	17.68	24.63
	Fast	mRNA vaccine	11.8	12.84	13.72	15.25	22.20

Summary of the vaccine unit costs by country (n = 27) estimated for vaccine roll-out efforts starting in 01 August 2021 using medium and fast roll-out rates by vaccine types. The underlying methods have been described in Additional File 1: Methods S7-9. Raw data behind these estimates were presented in Additional File 1: Table S7-8. Further sample estimates by country are presented in Additional File 1: Table S9. In this study, vaccine delivery unit costs differ by country, vaccine type, vaccine roll-out rates, and programme duration

ISSN: 1741-7015